Immunotherapy Before and After Surgery Boosts Lung Cancer Outcomes
Pre- and post-surgical immunotherapy, combined with chemotherapy, improved survival rates for patients with operable non-small cell lung cancer in a phase 3 trial.
Pre- and post-surgical immunotherapy, combined with chemotherapy, improved survival rates for patients with operable non-small cell lung cancer in a phase 3 trial.
A notable signal of protection of 84% was observed against symptomatic influenza infection in a phase 2a study.
A clinical trial of a probiotic and herbal supplement for lung health yielded promising results, including improvements in lung functions and quality of life scores in participants.
Janssen had been enrolling participants in a phase 3 trial to demonstrate the efficacy of its RSV vaccine candidate in adults age 60 and older.
Read MoreIn preclinical mouse studies, CLB073 significantly enhanced the efficacy of Nix-TB drug regimen, the current standard of care for drug-resistant tuberculosis.
Read MoreThe trial evaluated the safety and immunogenicity of AAHI’s vaccine candidate compared to the previous iteration of the vaccine—a two-vial presentation that had demonstrated promising safety and immunogenicity in Phase 2 clinical testing.
Read MoreThe expansion of the clinical trial follows the clearance of an Investigational New Drug application by the US Food and Drug Administration, announced earlier this year.
Read MoreThe US Food and Drug Administration has accepted Merck’s new supplemental Biologics License Application based on data from the trial.
Read MoreA multisite clinical trial will evaluate an investigational COVID-19 antiviral known as the Shionogi antiviral (S-217622) or ensitrelvir fumaric acid.
Read MoreBiomX has announced positive data from a study assessing the safety and tolerability of BX004 in nine cystic patients.
Read MoreThe trial will assess the safety, tolerability, and immunogenicity of the IIV4 candidate in approximately 150 healthy participants, aged 18 to 50.
Read MoreThe target action date for the FDA’s approval decision is set for the third quarter. If approved, nirsevimab is expected to be available in the US for the 2023/2024 RSV season.
Read MorePhase 3 data found the Moderna RSV vaccine was 83.7% effective against RSV-associated lower respiratory tract disease in adults age 60 and older. The FDA has granted the vaccine a Breakthrough Therapy Designation.
Read MoreThe FDA accepted Biologics License Applications and granted priority review for both Pfizer and GSK’s RSV older adult vaccine candidates last year following positive data from phase 3 trials.
Read MoreA phase 3 clinical trial revealed that treatment with nebulized ensifentrine led to significant improvements in lung function, symptoms and quality of life measures in COPD patients.
Read More